Impact of Brokerage Rating on ResMed Inc.(RMD)

Many ResMed Inc.(RMD) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. ResMed was Upgraded by JP Morgan to Overweight on Jan 24, 2017. Company shares were Reiterated by Canaccord Genuity on Jan 24, 2017 to Hold, Raises Price Target to $ 59 from a previous price target of $55 .

Company has reported several Insider transactions to the SEC, on Feb 7, 2017, Peter C Farrell (director) sold 20,000 shares at 68.32 per share price.On Feb 6, 2017, David Pendarvis (Chief Administrative Officer) sold 6,365 shares at 67.16 per share price.On Jan 19, 2017, James Hollingshead (President, Americas) sold 7,084 shares at 64.44 per share price.

ResMed Last issued its quarterly earnings results on Jan 23, 2017. The company reported $0.73 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.70. The company had revenue of $530.40 million for the quarter, compared to analysts expectations of $516.28 million. The companys revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.69 EPS.

ResMed Inc. (NYSE:RMD) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.95 by 11 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 3 Brokerage Firms have advised hold. 3 Analysts have rated it as strong sell. A sell rating was given by 1 analyst.

ResMed Inc. (NYSE:RMD): The mean short term price target for ResMed Inc. (NYSE:RMD) has been established at $63.18 per share. The higher price target estimate is at $73 and the lower price target estimate is expected at $50 according to 9 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $8.5

ResMed Inc. (NYSE:RMD) rose 0.3% or 0.21 points on Tuesday and made its way into the gainers of the day. After trading began at $70.38 the stock was seen hitting $71.23 as a peak level and $70.38 as the lowest level. The stock ended up at $71.07. The daily volume was measured at 802,107 shares. The 52-week high of the share price is $71.23 and the 52-week low is $55.13. The company has a market cap of $10,068 million.

ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors.

ResMed

Share this post

Post Comment